Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Huilun Pharmaceutical

    • Home
    • Huilun Pharmaceutical
Company Deals

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform

Fineline Cube Dec 17, 2025

Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) and Shanghai Huilun Pharmaceutical Co., Ltd....

Recent updates

  • Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline
  • GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic
  • Beijing Friendship Hospital Launches Cell and Gene Therapy Center for Liver Diseases
  • Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal
  • Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Company Drug

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

Hospital

Beijing Friendship Hospital Launches Cell and Gene Therapy Center for Liver Diseases

Company Deals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.